ADXN
Addex Therapeutics Ltd
NASDAQ · Healthcare · Biotechnology · CH
$3.65
−1.62%Year over year
Reported trailing growth
- Revenue
- -56.6%
- EBITDA
- -29.5%
- EBIT
- -4.5%
- EPS
- —
- Free cash flow
- +38.4%
- Operating cash flow
- +38.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -72.4%
- EBITDA
- -47.1%
- EBIT
- -2.2%
- Net income
- —
- EPS
- —
- Free cash flow
- +61.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026